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Abstract We demonstrated recently that coagulation factor IX 
has a specific binding site(s) for Mg 2÷ ions, independent of the 
Ca2÷-binding sites, and that binding of Mg 2+ ions is very 
important for expression of the functional conformation of this 
protein. We report here the localization of this Mg2+-specific 
binding site. We prepared three Gla-containing fragments of 
bovine factor IX, namely GIaEGFNc (residues 1-144+286-296), 
GlaEGFN (1-83) and the Gin domain peptide (1-46). Fragments 
GIaEGFN¢ and GIaEGFN retained the ability to undergo a 
conformational change upon binding of Mg z÷ ions in the presence 
of excess Ca 2+ ions. This change could be detected by a 
conformation-specific antibody. Furthermore, the Gla domain 
peptide was capable of binding Mg 2÷ ions, as determined by the 
metal ion-induced quenching of the intrinsic fluorescence. It 
appears that the Mg2÷-specific binding site of factor IX is 
located in the N-terminal Gla domain. 
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1. Introduction 
Coagulation factor IX is a serine protease zymogen that is 
indispensable for normal hemostasis [1]. Factor IX, resem- 
bling other vitamin K-dependent coagulation proteins, re- 
quires Ca 2+ ions at physiological concentrations (in the mM 
range) for maintenance of its native functional conformation 
[2,3]. We demonstrated recently that Mg 2+ ions, present nor- 
mally in blood plasma, also play an important role in the 
stabilization of the native conformation of factor IX and 
thus in the expression of its biological activities [4]. Various 
Gla domain-directed probes (several preparations of confor- 
mation-specific antibodies and IX/X-bp, a snake venom anti- 
coagulant protein [5,6]) specifically recognize the Ca2+-bound 
conformation of factor IX. We showed that the binding of 
such probes was much enhanced by Mg 2+ ions at levels in 
plasma in the presence of Ca 2+ ions, even though Mg 2+ ions 
alone did not promote the binding of each probe. It is known 
that Ca2+-binding sites of factor IX can interact with other 
polyvalent cations, but our results clearly indicated that this 
protein has a specific binding site(s) for Mg 2+ ions, independ- 
ent of Ca2+-binding sites, and that binding of Mg 2+ ions in- 
duces an additional conformational change even when all the 
Ca2+-binding sites are already occupied. The biological activ- 
ity of factor IX was potentiated by the cation, concomitant 
with its effect on the conformation. We revealed that Ca 2+- 
dependent conversion by factor XIa of factor IX to factor IXa 
was accelerated by the addition of Mg 2+ ions [4]. More re- 
cently, we also showed that all the factor IX/IXa-dependent 
reaction steps in coagulation are greatly augmented by Mg 2+ 
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ions and definitively proved that the cation is a crucial con- 
stituent of the blood coagulation cascade [7]. 
Binding sites for Ca 2+ ions in vitamin K-dependent coagu- 
lation factors, including factor IX, have been extensively stud- 
ied. The N-terminal Gla domains are the common Ca~+-bind - 
ing sites in all cases [2,3]. Seven Ca 2+ ions and the amino acid 
residues that act as Ca2+-binding ligands have been identified 
by X-ray crystallography of prothrombin fragment 1 [8]. In 
addition to the Gla domain, factor IX (as well as factors VII, 
X and protein C) has two other Ca2+-binding sites. The pri- 
mary structures and the domain organizations of these pro- 
teins resemble one another; each of them has, adjacent o a 
Gla domain, two tandem repeats of an EGF domain, an ac- 
tivation peptide and a serine protease catalytic domain. The 
first EGF domain [9] and the catalytic domain [10] are cap- 
able of binding Ca 2+ ions. Although various polyvalent metal 
ions can also interact with some of these Ca2+-binding sites, 
specific binding sites for metal ions other than Ca 2+ ions, such 
as Mg 2+ ions, have not yet been identified. In the present 
study, we tried to locate the Mg2+-specific binding site in 
factor IX in order to establish a biochemical basis for the 
interaction between factor IX and Mg 2+ ions. 
2. Experimental 
2.1. Preparation of factor IX fragments 
Bovine factor IX was prepared by the published method [11]. The 
fragments designated GIaEGFN¢ and GIaEGFx were prepared by the 
method of Valcarce et al. [12]. In the original report [12], it was stated 
that GlaEGFN underwent stoichiometric internal cleavage at GluT°/ 
Cys 71. We failed to detect such a cleavage upon sequence analysis; 
little if any such intramolecular cleavage occurred in our preparation. 
The Gla domain (1-46) peptide was prepared from GlaEGFNc as 
follows. One mg of GlaEGFNc was dissolved in 1 ml of 20 mM 
Tris.HC1, pH 7.5, and digested with endoproteinase Asp-N (E/ 
S = 1:500, w/w; Boehringer Mannheim) at 37°C for 12 h. The digest 
was loaded onto Mono-Q 5/5 (Pharmacia) preequilibrated with the 
same buffer and the column was developed with a gradient of NaCI 
(04).8 M) over 40 min at a flow rate of 1 ml/min. The Gla domain (1 
46) fragment was eluted in 0.4 M NaC1, as the last protein peak. The 
yield was 0.2 mg. 
2.2. ELISA 
The ELISA was performed as reported previously [4]. We used a 
monoclonal ntibody (4A4; subclass IgG1, ~), that recognizes Ca 2+- 
bound conformation of the Gla domain of factor IX. The presence of 
the epitope of this antibody in the Gla domain was confirmed by 
immunoblotting analysis with the isolated Gla domain peptide (H. 
Atoda and T. Morita, unpublished observation). The antibody was 
selected from the panel of monoclonal antibodies, which had been 
prepared by immunization with the human protein [4], but later 
shown also to be reactive to the bovine protein. 
2.3. Fluorescence quenching 
A 1000-1al liquot of the Gla domain (1-46) peptide (5 ~tM) in 20 
mM Tris-HCl, 140 mM NaC1, pH 7.5, was placed in a micro-quartz 
cell. Two and one-half microliters of 4 M calcium chloride and/or 2.5 
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Ixl of 0.4 M magnesium chloride solution was added to the sample, 
and the fluorescence spectrum was recorded after each addition with 
excitation at 280 nm in a spectrofluorometer (model FP-777; JASCO, 
Tokyo, Japan). 
3. Results 
As we showed previously [4], the Gla domain of factor IX 
(both human and bovine) undergoes further conformational 
change upon addition of Mg 2+ ions in the presence of Ca 2+ 
ions. We postulated that the Mg2+-specific binding site should 
be located within or Laear the Gla domain. To verify this 
possibility, we prepared several Gla domain-containing pro- 
teolytic fragments of bovine factor IX as shown in Fig. 1. The 
GlaEGFNc and GlaEGFN fragments were prepared by the 
published method [12], and the Gla domain (1-46) peptide 
was prepared by Asp-N digestion of GIaEGFNc. The prepara- 
tion of the Gla domain (residues 1-42) by chymotryptic diges- 
tion has been reported [13], but we preferred to use the longer 
fragment because the aromatic amino acid stack domain (the 
short linker between the Gla domain and the first EGF do- 
main; residues 41-46) is important for correct folding of the 
Gla domain [14,15]. The identity of each fragment was con- 
firmed by analysis of the sequence and/or composition of 
amino acids. 
We first examined the binding of the conformation-specific, 
Gla domain-directed monoclonal antibody, 4A4, the binding 
of which is absolutely dependent on Ca 2+ ions. As is shown in 
Fig. 2, the extent of binding of the probe to GlaEGFNc and 
GlaEGFN was augmented by the addition of Mg 2+ ions as 
observed in the case of the intact molecule. Magnesium ions 
were effective even in the presence of excess Ca 2+ ions but 
were ineffective in the absence of Ca 2+ ions. Thus, the 
Mg2+-specific binding site was located within GlaEGFN. By 
contrast, we failed detect any binding of the 4A4 antibody to 
the Gla domain peptide at any tested concentrations of Ca 2+ 
ions or of the antibody (data not shown). This failure was 
probably attributable both to the low efficacy of immobiliza- 
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tion of the small peptide on the assay plate and to the de- 
crease in binding affinity of the antibody upon fragmentation 
of the antigen. Nevertheless, it appeared that the middle and 
the C-terminal portions of factor IX, i.e., the second EGF 
domain (EGFc), the activation peptide and the catalytic do- 
main, were unnecessary for the recognition of Mg 2+ ions, 
while the N-terminal portion, the Gla domain or the first 
EGF domain (EGFN), included the specific binding site for 
Mg 2+ ions. 
To narrow down still further the location of the binding 
site, we employed a physicochemical pproach. The Gla do- 
main of factor IX contains a single tryptophan residue at the 
42nd position and, upon binding of metal ions, fluorescence 
derived from this residue is quenched concomitant with the 
conformational rearrangement of this domain [15]. Changes in 
the fluorescence spectrum of the Gla domain peptide in an 
isotonic, neutral buffer were recorded after addition of Ca 2+ 
and/or Mg 2+ ions with excitation at 280 nm (Fig. 3). A de- 
crease in intrinsic fluorescence was observed upon addition of 
Ca 2+ ions. Together with the decrease in fluorescence inten- 
sity, a blue-shift was seen, indicating that the observed 
quenching was not due to mere aggregation of the peptide 
but rather represented a change in the conformation. The 
quenching reached a plateau when the concentration of 
Ca 2+ ions was sufficiently high (> 1 mM), in agreement 
with the reported result with a synthetic Gla domain peptide 
of human factor IX [15]. Further addition of Ca 2+ ions did 
not alter the fluorescence, an indication that all the Ca 2+- 
binding sites had been occupied and the conformational 
change had been completed. However, when we added a rel- 
atively low concentration of Mg 2÷ ions (1 mM) in the pre- 
sence of a supermaximal concentration of Ca 2+ ions (10 mM), 
a significant decrease in fluorescence was observed (Fig. 3). 
This result indicated that the Mg2+-specific binding site was 
located in the N-terminal Gla domain (between residues 1and 
46) and that occupation of this site by the cation induced a 
conformational change in this domain, which could be de- 
tected as a change in the micro-environment around Trp 42. 
EGFc 
415 
Factor IX 
144 286 296 
A 
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Gla EGFNc 
83 
A GlaEGFN 
46 
Fig. 1. Structures of factor IX fragments. The fragments used in this study are shown schematically. Gla, the Gla domain; A, the aromatic 
amino acid stack domain; AP, the activation peptide. The symbol Y denotes Gla residue(s). The domains that contain Ca2+-binding site(s) are 
shaded. 
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Fig. 2, Enhancement of binding of the conformation-specific antibody by Mg 2+ ions. The binding of the monoclonal ntibody 4A4 that recog- 
nized the Ca2+-bound conformation of factor IX to the intact molecule (A), GlaEGFNc (B) and GlaEGFN (C) was investigated by ELISA in 
the presence of indicated concentrations of Ca 2+ ions. e, Ca 2+ alone; O, Ca 2+ plus 3 mM Mg 2+. 
4.  D iscuss ion  
We showed previously that factor IX has a specific binding 
site(s) for Mg 2+ ions, which does not interact with Ca 2+ ions 
[4]. We showed clearly here that this Mg2+-specific site is 
located between residues 1 and 46, namely in the Gla domain 
of factor IX. The fragment GlaEGFN underwent a conforma- 
tional change that was detectable as an increase in binding of 
a conformation-specific probe upon the addition of Mg 2+ ions 
even in the presence of excess Ca 2+ ions, and the binding 
profile was very similar to that of the intact molecule. 
Furthermore, the isolated Gla domain peptide still retained 
the ability to respond to Mg 2+ ions, as was apparent from 
the observed changes in intrinsic fluorescence. We were unable 
to narrow down the site any further because current meth- 
odologies cannot be applied to smaller fragments. Deletion of 
a few C-terminal residues of the Gla domain peptide had a 
considerable effect on the folding of this module; a synthetic 
peptide corresponding to residues 1-42 of the human protein 
no longer responds to metal ions in the fluorescence quench- 
ing assay [15]. For unequivocal identification of the ligands of 
the Mg 2+ ion, further investigations that can provide more 
detailed structural information (e.g., X-ray crystallography 
and NMR spectrometry) are necessary. 
The effects of Mg 2+ ions on factor IX were seen with both 
the human and the bovine protein. However, we failed to 
detect any such effect with other vitamin K-dependent coagu- 
lation proteins, i.e., prothrombin, factors VII, X and protein 
C [4]. This result is noteworthy, since the primary structures 
of these proteins, in particular those of Gla domains, are very 
similar. Furthermore, in view of their common function, 
namely the Ca2+-dependent binding to anionic phospholipids, 
we would expect their tertiary structures also to be similar. 
With these considerations in mind, we compared the primary 
structure of the Gla domain of factor IX with those of the 
other proteins (Fig. 4). Although a very high degree of simi- 
larity was found when we compared the entire sequences of 
each protein, significant differences unique to factor IX were 
found mainly in the N-terminal portion. (1) The first residue 
of factor IX is tyrosine, while the others all have alanine at 
this position. (2) Insertion of glycine as the fourth residue 
occurs in factor IX. (3) A cluster of three hydrophobic resi- 
dues followed by a basic residue (in human factor X, 
FLyyVK, residues 4~9), which constitute the putative binding 
site for phospholipids [16], is well conserved in this family but, 
in factor IX, it is changed to KLwF.._y_v in the human and 
bovine proteins. It is thus possible that these residues unique 
to factor IX act as ligands for a Mg 2+ ion, though we cannot 
exclude possibility of the participation of the C-terminal por- 
tion, where some difference is also found. Changes in amino 
acid residues hould induce changes in tertiary structure. It is 
possible that the size of metal-binding pocket formed by these 
residues is reduced such that a Ca 2+ ion can no longer gain 
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Fig. 3. Metal ion-induced quenching of the intrinsic fluorescence of 
the Gla domain (1-46) peptide. Fluorescence spectra of the peptide 
(5 ktM) were recorded after excitation at 280 nm with no additions 
(top trace), with 10 mM Ca 2+ (middle) and with Ca 2+ plus 1 mM 
Mg 2+ (bottom). The decrease i n  fluorescence due to changes in vol- 
ume was negligible. 
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Fig. 4. Primary structures of Gla domains of various vitamin K-de- 
pendent coagulation factors. N-Terminal sequences of bovine [20] 
and human [21] factor IX, human factor X [22], human factor VII 
[23], human protein C (PC) [24] and human prothrombin (PT) [25] 
are aligned. Residues identical to those in both human and bovine 
factor IX are shaded. 7, Gla residue. 
access but a Mg 2+ ion, which has a smaller ionic radius (0.86 
A) than a Ca 2-- ion (1.14 A), can bind within the pocket. 
Upon binding of Mg 2+ ions, the biological activities of 
factor IX are considerably enhanced [4,7]. The rate of activa- 
tion of factor IX by factor XIa is increased with a striking 
reduction in the apparent Km [4]. Although the activation by 
factor XIa requires Ca 2+ ions at around 1 mM, the concen- 
tration at which the conformational change of the Gla do- 
main occurs, the Gla domain does not participate directly in 
the interaction of the enzyme and the substrate [15]. There- 
fore, it appears that the conformational rearrangement of the 
Gla domain upon binding of Ca 2+ ions induces a secondary 
conformational rearrangement of the whole molecule such 
that the cleavage sites (Arg145/Ala 46 and ArglS°/Va1181) in 
factor IX become more accessible to the activator. Our finding 
that the Mg2+-specific binding site is located in the Gla do- 
main indicates, therefore, that the Mg2+-induced change in 
the conformation of the Gla domain also modulates the ter- 
tiary structure of the entire molecule. The structure of factor 
IX that is stabilized by both Ca z+ and Mg 2+ ions should 
represent the actual conformation i  blood plasma. Recently, 
the solution structures of a synthetic peptide that corre- 
sponded to the Gla domain of human factor IX (residues 1 
47) both in Ca2+-free and Ca2+-bound forms were resolved by 
NMR spectrometry [17,18]. Furthermore, a X-ray crystallo- 
graphic structure of porcine factor IXa[3 was also reported (in 
this case, the N-terminal portion was invisible as a conse- 
quence of the absence of metal ligands that stabilize the con- 
formation of this region) [19]. Our investigations indicate, 
however, that these structural studies must be re-examined 
in view of the demonstrated effect of Mg 2+ ions (i.e. in the 
presence of both Ca 2+ and Mg 2+ ions) for the clarification of 
the exact 'native' conformation of this important protein. 
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